The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 10, 2023
Filed:
Dec. 06, 2018
Applicant:
Millennium Pharmaceuticals, Inc., Cambridge, MA (US);
Inventors:
Pingda Ren, San Diego, CA (US);
Yi Liu, San Diego, CA (US);
Liansheng Li, San Diego, CA (US);
Katrina Chan, Fremont, CA (US);
Troy Edward Wilson, Rolling Hills Estates, CA (US);
Simon Fraser Campbell, Poole, GB;
Assignee:
MILLENNIUM PHARMACEUTICALS, INC., Cambridge, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/423 (2006.01); A61K 31/444 (2006.01); A61K 31/437 (2006.01); A61K 31/517 (2006.01); A61K 31/5025 (2006.01); A61K 31/496 (2006.01); A61K 31/4709 (2006.01); A61K 31/5377 (2006.01); A61K 31/498 (2006.01); A61K 31/541 (2006.01); A61K 31/551 (2006.01); A61K 31/497 (2006.01); A61K 31/428 (2006.01); C12N 9/12 (2006.01); C07D 413/04 (2006.01); C07D 413/14 (2006.01); C07D 417/04 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 519/00 (2006.01); C07D 401/14 (2006.01);
U.S. Cl.
CPC ...
A61K 31/423 (2013.01); A61K 31/428 (2013.01); A61K 31/437 (2013.01); A61K 31/444 (2013.01); A61K 31/4709 (2013.01); A61K 31/496 (2013.01); A61K 31/497 (2013.01); A61K 31/498 (2013.01); A61K 31/5025 (2013.01); A61K 31/517 (2013.01); A61K 31/5377 (2013.01); A61K 31/541 (2013.01); A61K 31/551 (2013.01); C07D 401/14 (2013.01); C07D 413/04 (2013.01); C07D 413/14 (2013.01); C07D 417/04 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07D 519/00 (2013.01); C12N 9/1205 (2013.01); Y02A 50/30 (2018.01);
Abstract
Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.